STOCK TITAN

Acrivon Therapeutics, Inc. - $ACRV STOCK NEWS

Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: $ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acrivon Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acrivon Therapeutics's position in the market.

Rhea-AI Summary
Acrivon Therapeutics announces internally developed clinical candidate ACR-2316, a dual WEE1 and PKMYT1 inhibitor. IND submission planned by Q4 2024. AP3 platform enables rapid generation and optimized design of ACR-2316. Potential for monotherapy development in tumors predicted to be sensitive to ACR-2316 using OncoSignature patient selection approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
-
Rhea-AI Summary
Acrivon Therapeutics to participate in two investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. has approved a grant of equity awards to an employee under its 2023 Inducement Plan. The employee received 14,475 restricted stock units (RSUs) and an option to purchase 43,425 shares of Acrivon common stock. The RSUs will vest in 25% annual increments on the first anniversary of the employee's employment, while the stock options will vest 25% on the first anniversary and in additional 2.083% installments on a monthly basis thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
Rhea-AI Summary
Acrivon Therapeutics reports financial results for Q2 2023 and provides business highlights. The company made progress in clinical and preclinical development, expanded its board and executive team, and enrolled patients in a Phase 2 study. They are focused on the successful execution of the study and look forward to sharing clinical data later this year. Acrivon also highlighted the broad utility of its AP3 platform and its upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.81%
Tags
-
Rhea-AI Summary
Acrivon Therapeutics has announced the appointment of Adam D. Levy, Ph.D., M.B.A., as senior vice president and head of investor relations and corporate affairs. Dr. Levy brings more than 25 years of experience in the biopharma industry, with previous roles at Zentalis Pharmaceuticals, Turning Point Therapeutics, and Gilead Sciences. Acrivon is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary proteomics-based patient responder identification platform. The company's lead clinical candidate, ACR-368, is currently in Phase 2 registrational-intent trials for multiple solid tumors. Dr. Levy's appointment reflects Acrivon's commitment to enhancing its communications and corporate affairs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences
Acrivon Therapeutics, Inc.

Nasdaq:ACRV

ACRV Rankings

ACRV Stock Data

264.00M
3.98M
17.57%
69.76%
2.35%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WATERTOWN

About ACRV

acrivon therapeutics is a biotech company specializing in drug development through early clinical treatment success using our unique predictive biomarker approach. our technology platform is based on integrating drug-regulated, global proteomics with focused intact tissue digital imaging to develop drug-tailored biomarker signatures for prospective patient responder identification. the foundational science is based on proven, pathway-based methods linking active disease-driving mechanisms with the drug mechanism-of-action, to precisely match the therapy with patients who will benefit. our method is applicable across drug modalities